Curaleaf International Expands Medical Cannabis Education Platform for Healthcare Professionals in Poland

LONDON, Oct. 8, 2026 /PRNewswire/ -- Curaleaf International has announced the launch of the Curaleaf Education Platform in Poland, giving healthcare professionals across the country free access to structured, clinical training in medical cannabis.

Available at curaleafeducation.com, the platform delivers a comprehensive learning curriculum spanning foundational science, core clinical knowledge and specialist therapeutic areas. The syllabus is tailored to the distinct roles of family doctors, consultant-level clinicians and pharmacists within the regulated prescribing framework in Poland.

Medical cannabis has been legal in Poland since 2017, and there are approximately 250,000 patients prescribed this medicine, yet formal education on the endocannabinoid system and cannabis-based medicines remains limited within mainstream medical training. As patient awareness grows, clinicians are increasingly encountering questions about medical cannabis without access to structured learning resources to support informed, confident conversations and clinical guidelines.

The courses have been reviewed by the Curaleaf Advisory Board, made up of international consultants, ensuring all material is verified, grounded in current evidence and aligned with local prescribing frameworks. The syllabus is structured across five courses:

• Foundations of Medical Cannabis: the science of phytocannabinoids and the endocannabinoid system
• Core Knowledge for Clinical Practice: products and formulations, safety profile and risk management, and prescribing and clinical management
• Specialist Conditions: Evidence and Application: dedicated modules on
  • Pain (including Chronic Pain, Endometriosis, Rheumatology and Palliative Care)
  • Neurology (including Parkinson's disease, Epilepsy, MS and Insomnia)
  • Psychiatry (including Anxiety, Depression, PTSD, ADHD, and ASD)

The content draws on global research as well as Curaleaf's real-world evidence database. The UK Medical Cannabis Registry, the largest clinical database of its kind in Europe, has over 55,000 patients. With over 40 peer reviewed publications, translating this evidence into practical guidance for everyday clinical decision-making, real-world evidence supports safe and informed prescribing.

Dr Paweł Dryżałowski, Medical Doctor and Founder, Curaleaf Centrum Medyczne, Poland, said:

"Cannabis-based medicine in Poland operates within a clearly defined legal and regulatory framework. However, in practice, levels of knowledge, experience, and confidence in managing treatment may still vary among physicians, consultants, and pharmacists. In 2020, I founded one of the first clinics in Poland to manage patients using cannabis-based medicines (CBM), and since then I have seen how important it is for all professionals involved to work from a shared knowledge base in order to ensure a smooth and safe patient pathway. The Curaleaf Education Platform aims to provide healthcare professionals across Poland with a consistent standard of knowledge, regardless of their role in patient care."

Dr Mikael Sodergren, Chief Medical Officer at Curaleaf International, added:

"Education is fundamental to providing patients with the highest standard of care and access to medical cannabis. As part of our commitment to research, innovation and product excellence, we are proud to bring this resource to healthcare professionals in Poland. The clear, evidence-led modules give clinicians the confidence to integrate medical cannabis into their practice responsibly."

Curaleaf International's Education Platform is now live in Poland, alongside the UK, as part of the company's wider commitment to advancing responsible medical cannabis education across Europe.

Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.

Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four 20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.

For all press enquiries, please contact media@curaleafint.com